Holocene Advisors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Holocene Advisors’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-6,129	Closed	-$294K	–	817
2020 Q2	$294K	Buy	+6,129	New	+$473K	﹤0.01%	565
2018 Q2	–	Sell	-4,038	Closed	-$248K	–	760
2018 Q1	$248K	Sell	4,038 -5,770	-59%	-$348K	0.01%	455
2017 Q4	$573K	Buy	+9,808	New	+$619K	0.01%	375

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Holocene Advisors's ICPT Position: Q3 2020 in Review

Holocene Advisors sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2020, closing a stake of 6,129 shares — an estimated $294K sold.

Holocene Advisors first reported a position in ICPT in Q4 2017 and held it in 3 quarters. The position peaked at $573K in Q4 2017. 177 funds tracked by Wall St. Rank hold ICPT as of Q3 2020.

Holocene Advisors reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
Holocene Advisors sold 6,129 Intercept Pharmaceuticals, Inc. shares in Q3 2020, an estimated $294K.
Holocene Advisors first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2017 and held it in 3 quarters.
Holocene Advisors's Intercept Pharmaceuticals, Inc. position peaked at $573K in Q4 2017.
177 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2020.

Based on Holocene Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.